MTOR and tuberous sclerosis: Recent studies have shown promising results for mTOR inhibitors in preliminary clinical studies of patients affected by TSC, for both seizure reduction and other disease-modifying effects.14Recently, a neonate with HME without TSC started treatment with rapamycin, an mTOR inhibitor, due to intractable epilepsy pending hemispherectomy.15Within a week, seizure frequency was reduced by >50%, and developmental improvements were observed.